Aspire Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-12-2024
- Paid Up Capital ₹ 0.10 M
as on 05-12-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -13.84%
(FY 2017)
- Profit -16.89%
(FY 2017)
- Ebitda -25.87%
(FY 2017)
- Net Worth 16.55%
(FY 2017)
- Total Assets 0.08%
(FY 2017)
About Aspire Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rishi Mehta and Geeta Mehta serve as directors at the Company.
- CIN/LLPIN
U52300MH2009PTC193581
- Company No.
193581
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2009
- Date of AGM
19 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Aspire Lifesciences Private Limited offer?
Aspire Lifesciences Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Extracts, Herbal Extracts, Anti Infective Drugs & Medicines, Anti Infective Agent, Nutraceuticals & Dietary Supplements, Mineral Supplement, Pharma Ingredients & Raw Materials, Pharmaceutical Excipients, Packaging Films & Foils, Packaging Foil.
Who are the key members and board of directors at Aspire Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rishi Mehta  | Director | 26-Jun-2009 | Current |
| Geeta Mehta | Director | 20-Feb-2012 | Current |
Financial Performance of Aspire Lifesciences.
Aspire Lifesciences Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 13.84% decrease. The company also saw a substantial fall in profitability, with a 16.89% decrease in profit. The company's net worth Soared by an impressive increase of 16.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aspire Lifesciences?
In 2017, Aspire Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aspire Lifesciences?
Unlock and access historical data on people associated with Aspire Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aspire Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aspire Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
